Congresswoman: Novartis troubles call for more FDA oversight

California Congresswoman Mary Bono Mack said she is perplexed that FDA inspectors continued to cite problems at the Novartis ($NVS) Lincoln, NE, plant without holding the drugmaker accountable. The incident highlights "the lack of predictability and consistency" in FDA interactions with manufacturers, and "emphasizes the need for more FDA oversight," she writes to FDA head Margaret Hamburg. Letter

Suggested Articles

McCallum was hit with a warning letter from the FDA for testing issues with its products and failing to keep appropriate records.

The FDA made public a voluntary recall of sterile injectables made by Coastal Meds of Mississippi, after visible particles were found in some vials.

It’s been a strange road for BMS' Opdivo-Yervoy combo in first-line kidney cancer, but the New Jersey drugmaker finally has a go-ahead.